Opinion statement
Meningiomas are extra-axial brain tumors of middle to late adult life, and they have a female predominance. Overall, 90% of meningiomas are benign, 6% are atypical, and 2% are malignant. Most patients diagnosed with a meningioma decide to have it removed surgically and are advised to do so based on their neurologic symptoms. Complete surgical resection is usually curative. For incompletely resected or recurrent tumors not previously irradiated, radiotherapy is administered. Radiotherapy may be administered as conventional external beam irradiation or stereotactically. Stereotactic radiotherapy, as linear accelerator or gamma-knife radiosurgery is increasingly used. Advocates of stereotactic radiotherapy have suggested this therapy in lieu of surgery particularly for poor surgical risk patients, patients with meningiomas in eloquent or surgically inaccessible locations, and patients of advanced age. When the meningioma is unresectable or all other treatments (surgery, radiotherapy) have failed, immunochemotherapy may be considered. Hydroxyurea, interferon-alpha, tamoxifen, and mifepristone have been modestly successful in patients with recurrent meningiomas, whereas cyclophosphamide, adriamycin, and vincristine, ifosfamide/mesna, or adriamycin/dacarbazine have been administered to patients with aggressive or malignant meningiomas.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Bondy M, Ligon BL: Epidemiology and etiology of intracranial meningiomas: a review. J Neurooncol 1996, 29:197–205.
Wilson CB: Meningiomas: genetics, malignancy, and the role of radiation in induction and treatment. J Neurosurg 1994, 81:666–675. Although from 1994, this is an excellent overview of meningiomas and their management.
Olivero WC, Lister JR, Elwood PW: The natural history and growth rate of asymptomatic meningiomas: a review of 60 patients. J Neurosurg 1995, 83:222–224.
Braunstein JB, Vick NA: Meningiomas: the decision not to operate. Neurology 1997, 48:1459–1462. This is an important article that addresses the urgency (or not) of surgery in the initial management of meningiomas.
Firsching RP, Fischer A, Peters R, et al.: Growth rate of incidental meningiomas. J Neurosurg 1990, 73:545–547.
Go RS, Taylor BV, Kimmel DW: The natural history of asymptomatic meningiomas in Olmsted County, Minnesota. Neurology 1998, 51:1718–1720.
Niiro M, Yatsushiro K, Nakamura K, et al.: Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psych 2000, 68:25–28.
Goldsmith BJ, Wara WM, Wilson CB, Larson DA: Postoperative irradiation for subtotally resected meningiomas. J Neurosurg 1994, 80:195–201. Although from 1994, this is the best series, again from a single institution, that provides a compelling rationale for external beam radiotherapy in subtotally resected meningiomas.
Kondziolka D, Lunsford D, Coffey RJ, Flickinger JC: Stereotactic radiosurgery of meningiomas. J Neurosurg 1991, 74:552–559.
Lunsford DL: Contemporary management of meningiomas: radiation therapy as an adjuvant and radiosurgery as an alternative to surgical removal? J Neurosurg 1994, 80:187–190.
Morita A, Coffey RJ, Foote RL, et al.: Risk of injury to cranial nerves after gamma knife radiosurgery for skull base meningiomas: experience in 88 patients. J Neurosurg 1999, 90:42–50. The largest contemporary series that addresses the role of SRT in the management of meningiomas.
Kyritisis AP: Chemotherapy for meningiomas. J Neurooncol 1996, 29:269–272.
Schrell UMH, Rittig MG, Anders M, et al.: Hydroxyurea for treatment of unresectable and recurrent meningiomas. J Neurosurg 1997, 86:845–852. This is a laboratory and clinical trial that established the use of hydroxyurea in the treatment of recurrent meningiomas.
Mason WP, Gentili F, Macdonald DR, et al.: Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002, 97:341–346.
Grunberg SM, Weiss M: Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol 1990, 8:61–65.
Grunberg SM, Weis M, Spitz IM, et al.: Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991, 74:861–866. Although from 1991, this is the only series that describes the use of mifepristone for recurrent meningiomas.
Wöber-Bringöl Ç, Wöber C, Marosi C, Prayer D: Interferonalfa-2b for meningioma. Lancet 1995, 345:331.
DeMonte F, Bruner JM, Kyritsis AP, et al.: The treatment of recurrent unresectable and malignant meningiomas with interferon alpha-2B. Neurosurgery 1997, 40:271–275. This is the largest series relating a single institution’s experience with interferon-alpha in the treatment of recurrent meningiomas.
Baumgartner JE, Sorenson JM: Meningioma in the pediatric population. J Neurooncol 1996, 29:223–228.
Mirimanoff RO, Dosoretz DE, Linggood RM, et al.: Meningioma: analysis of recurrence and progression following neurosurgical resection. J Neurosurg 1985, 62:18–24.
Jaaskelainen J: Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients: a multivariate analysis. Surg Neurol 1986, 26:261–469.
Gutman DH, Donahoe J, Perry A: Loss of DAL-1, a protein 4.1 -related tumor suppressor, is an important early event in the pathogenesis of meningiomas. Hum Mol Genet 2000, 9:1495–1500.
Antinheimo J, Sankila R, Carpen O, et al.: Populationbased analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology 2000, 54:71–78.
Sadetzki S, Flint-Richter P, Ben-Tal T, Nass D: Radiationinduced meningioma: a descriptive study. J Neurosurg 2002, 97:1078–1082.
King A, Gutmann DH: The question of familial meningiomas and schwannomas. Neurology 2000, 54:4–5.
Newton HB, Slivka MA, Stevens C: Hydroxyurea chemotherapy for unresectable or residual meningioma. J Neurooncol 2000, 49:165–170.
Chamberlain MC: Malignant meningiomas: adjunct combined modality therapy. J Neurosurg 1996, 84:733–736.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chamberlain, M.C. Intracerebral meningiomas. Curr Treat Options Neurol 6, 297–305 (2004). https://doi.org/10.1007/s11940-004-0029-0
Issue Date:
DOI: https://doi.org/10.1007/s11940-004-0029-0